Sangamo Therapeutics (NASDAQ:SGMO) Stock Passes Above 200 Day Moving Average - What's Next?

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.71 and traded as high as $2.00. Sangamo Therapeutics shares last traded at $1.70, with a volume of 11,244,344 shares traded.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. StockNews.com assumed coverage on shares of Sangamo Therapeutics in a research note on Sunday, July 28th. They set a "sell" rating for the company. HC Wainwright restated a "buy" rating and set a $5.00 price target on shares of Sangamo Therapeutics in a research note on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $2.67.

Sangamo Therapeutics Trading Up 10.6 %

The company's fifty day moving average is $1.00 and its 200 day moving average is $0.73. The company has a market capitalization of $391.45 million, a P/E ratio of -1.36 and a beta of 1.23.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01). The business had revenue of $0.36 million during the quarter, compared to the consensus estimate of $11.40 million. Sangamo Therapeutics had a negative return on equity of 273.25% and a negative net margin of 2,033.69%. Equities research analysts predict that Sangamo Therapeutics, Inc. will post -0.47 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its holdings in Sangamo Therapeutics by 58.8% in the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company's stock valued at $1,479,000 after purchasing an additional 1,528,600 shares during the period. Acadian Asset Management LLC lifted its holdings in shares of Sangamo Therapeutics by 4.0% during the 1st quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company's stock worth $3,311,000 after acquiring an additional 192,385 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Sangamo Therapeutics by 56.3% during the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company's stock worth $207,000 after acquiring an additional 207,476 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its holdings in shares of Sangamo Therapeutics by 61.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 23,650 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Sangamo Therapeutics during the 2nd quarter worth $67,000. 56.93% of the stock is owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.